Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Purchases To Hit 8% Of Outpatient Brand Drug Sales In 2019 – White Paper

This article was originally published in The Pink Sheet Daily

Executive Summary

Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.

You may also be interested in...



Hospital Drug Discount Transparency Bill Faces Heavy ‘Lift’ In Congress

But biopharma industry can help drive reform of 340B discounts by emphasizing how it might improve pricing, Rep. Chris Collins, R-NY, suggests.

Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill

House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.

340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs

A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.

Topics

UsernamePublicRestriction

Register

SC142271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel